Stocktoria

Enliven Therapeutics, Inc. ELVN

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-03-12

Enliven Therapeutics, Inc. statistics & valuation

Market cap$3.6B
P / B7.8×
Return on equity-22.6%
Return on capital-26%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2019202020212022202320242025
Operating margin (%)
2019202020212022202320242025
Return on equity (%)
-49.00% -29.10% -28.70% -22.60% 2019202020212022202320242025
Shares outstanding
702510 17.5M 26.3M 3.6M 41.3M 48.9M 59.4M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-70.50% -45.50% -54.90% -45.20% -26.30% -27.30% -21.80% 2019202020212022202320242025
Free cash flow margin (%)
2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$2.37 -$12.05 -$2.01 -$1.89 -$1.83 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Return on assets-21.8%-27.3%-26.3%-45.2%-54.9%-45.5%-70.5%
Return on equity-22.6%-28.7%-29.1%49.0%119.8%-49.0%48.0%
Current ratio28.6619.9910.288.0012.8614.477.29

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.